Moderna, Inc. (NASDAQ: MRNA) and OpenAI have announced a collaborative effort aimed at harnessing the potential of artificial intelligence (AI) to revolutionize both business and healthcare. Moderna, known for its digital-first approach and early adoption of machine learning, is poised to integrate generative AI into its operations seamlessly, building upon its strong data foundation and culture of continuous learning.
The partnership between the two organizations commenced in early 2023 with the introduction of mChat, Moderna’s customized instance of ChatGPT developed internally on OpenAI’s API. Since its inception, mChat has achieved over 80% internal adoption, catalyzing an AI-centric culture within Moderna. This initial success paved the way for the deployment of ChatGPT Enterprise, equipped with advanced features such as Advanced Analytics, Image Generation, and purpose-built GPTs tailored to various business functions, including legal, research, manufacturing, and commercial operations. These AI assistants complement Moderna’s workforce, providing personalized support and enhancing productivity across the board.
Stéphane Bancel, CEO of Moderna, emphasized the transformative potential of AI, drawing parallels to the revolution brought about by personal computers in the 1980s. He highlighted the shared values and research-driven approach of both Moderna and OpenAI, underscoring the importance of collaborations in scaling impact.
Sam Altman, CEO of OpenAI, commended Moderna’s commitment to empowering its employees with AI tools to address complex challenges. He expressed anticipation for further collaboration to bring innovative medicines to patients in need.
Since the adoption of ChatGPT Enterprise, Moderna has deployed over 750 GPTs, driving automation and enhancing productivity. Notably, the Dose ID GPT, utilizing ChatGPT Enterprise’s Advanced Data Analytics feature, assists in evaluating optimal vaccine doses selected by the clinical study team. This AI-driven approach prioritizes safety and optimizes vaccine dose profiles, facilitating informed decision-making during late-stage clinical trials.
For further insights into the collaboration between Moderna and OpenAI, interested parties can watch an overview video and access a detailed case study.
Moderna is at the forefront of mRNA medicine, leveraging mRNA technology to revolutionize disease treatment and prevention. With a decade-long commitment to science, technology, and health, Moderna has developed medicines with unprecedented speed and efficacy, including leading COVID-19 vaccines. The company’s mRNA platform enables the development of therapeutics and vaccines across various medical domains, driven by a global team dedicated to transforming human health.
Forward-Looking Statements:
This press release includes forward-looking statements regarding Moderna’s digital and AI initiatives and their potential impact on business operations. These statements are subject to risks, uncertainties, and other factors beyond Moderna’s control, which could cause actual results to differ materially. Moderna disclaims any obligation to update forward-looking statements based on new information or future events.
For more information about Moderna, visit modernatx.com and engage with the company on social media platforms.
